Physician profile
Robert E Jones
NPI 1255331021
$7,706.30
in general payments reported to CMS, 2019-2025
35 companies · $858 in 2025
The $858 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $1,167 · 2021: $1,488 · 2022: $1,372 · 2023: $757 · 2024: $813 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $994.19 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $867.13 | 2019-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $858.04 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $793.95 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $744.45 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $397.00 | 2019-2025 | Gardasil 9, Vaxneuvance, Verquvo |
| Amgen INC. | $275.00 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $269.36 | 2021-2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $258.34 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $257.20 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $241.69 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $202.98 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.15 | 2019-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $182.55 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Allergan, INC. | $135.10 | 2019-2020 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.